ID   B16
AC   CVCL_F936
SY   B-16; B16 melanoma; B16 subline B78; B78
DR   CLO; CLO_0050752
DR   CCRID; 1101MOU-PUMC000215
DR   CCRID; 1101MOU-PUMC000324
DR   CCRID; 5301MOU-KCB14029YJ
DR   ChEMBL-Cells; CHEMBL3308454
DR   ChEMBL-Targets; CHEMBL381
DR   CLS; 305154
DR   KCB; KCB 93030YJ
DR   KCB; KCB 2014029YJ
DR   PubChem_Cell_line; CVCL_F936
DR   RCB; RCB1283
DR   TKG; TKG 0144
DR   TOKU-E; 3564
DR   Wikidata; Q25112368
RX   PubMed=1109790;
RX   PubMed=4981070;
RX   PubMed=5513504;
RX   PubMed=6498800;
CC   Doubling time: ~28 hours (Note=Lot 07242000), 20-21 hours (Note=Lot 06122003), ~1 day (Note=Lot 10062005), ~20 hours (Note=Lot 03232009), ~27 hours (Note=Lot 03312017), ~33 hours (Note=Lot 01122021) (JCRB=JCRB0202).
CC   Miscellaneous: This line seems to be the B78 line described in PubMed=4981070 which itself seems to be derived from the HFH-18 line that itself originate from a B16 melanoma.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Breed/subspecies: C57BL/6.
DI   NCIt; C21790; Mouse melanoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_GS32 ! HFH-18
SX   Male
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 29-06-23; Version: 19
RX   PubMed=1109790;
RA   Fidler I.J.;
RT   "Biological behavior of malignant melanoma cells correlated to their
RT   survival in vivo.";
RL   Cancer Res. 35:218-224(1975).
RX   PubMed=4981070; DOI=10.1083/jcb.43.2.263;
RA   Silagi S.;
RT   "Control of pigment production in mouse melanoma cells in vitro.
RT   Evocation and maintenance.";
RL   J. Cell Biol. 43:263-274(1969).
RX   PubMed=5513504; DOI=10.1093/jnci/45.4.789;
RA   Stephenson E.M., Stephenson N.G.;
RT   "Karyotype analysis of the B16 mouse melanoma with reassessment of the
RT   normal mouse idiogram.";
RL   J. Natl. Cancer Inst. 45:789-800(1970).
RX   PubMed=6498800; DOI=10.1016/0304-3835(84)90080-6;
RA   Wosko T.J., Ferrara D.T., Sartori L.S.;
RT   "Histological comparison of the B16 melanoma and its F1 variant.";
RL   Cancer Lett. 24:57-63(1984).